ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Anavo Therapeutics BV
Netherlands
- Leiden, South Holland
- 04/05/2023
- Seed
- $9,406,482
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.
Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
- Industry Biotechnology Research
- Website https://www.anavotx.com/
- LinkedIn https://www.linkedin.com/company/anavo-therapeutics-bv/
Related People
Birgit ZechFounder
Germany -
ND
• 20 years working experience in Biotech, 15+ years in Business Development
• In depth knowledge of the pharmaceutical and biotech industry
• Excellent track record in deal making and fundraising
• Strong network to leading Pharma and Biotech companies, significant partnering experience in EP, US and JP
• Over 5 years experience in IP management
• Strong background in chemistry (small molecules, kinase inhibitors, protein modeling) and biology (antibodies, next generation scaffolds)
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)